| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 26.6 | 42.2 | 34.6 |
| Other income | 1.9 | 1.8 | 0.6 |
| Total income | 28.5 | 44.0 | 35.2 |
| Profit before exceptional items & tax | 0.1 | 2.6 | 3.4 |
| Profit before tax | 0.1 | 2.6 | 3.4 |
| Net profit | 0.1 | 2.7 | 3.4 |
| Operating margin | 0.4% | 5.9% | 9.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -97.10% |
|---|---|
| Net profit, quarter on quarter | -96.30% |
| Revenue, year on year | -23.10% |
| Operating profit, year on year | -164.30% |
| Operating profit, quarter on quarter | -325.00% |
Source
Read the filing ↗
BSE results filing, NSE: BAFNAPH. Figures extracted from the filing.
Bafna Pharmaceuticals Ltd: key numbers
- Share price
- ₹350.05
- Market cap
- ₹828.1 Cr
- Revenue (annual)
- ₹150.6 Cr
- Net profit (annual)
- ₹11.10 Cr
- P/E (TTM)
- 106.4×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 9.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bafna Pharmaceuticals Ltd
All →
15:03 IST
BSE
Annual General Meeting
Bafna Pharmaceuticals Annual General Meeting
Bafna Pharmaceuticals' 31st AGM held on September 11, 2026 approved adoption of audited financials, a director re-appointment, and cost auditor ratification. No specific monetary transaction was transacted.
18:32 IST
NSE
Financial Results
Bafna Pharmaceuticals Q4 FY26 Results: Net Profit ₹2.7 Cr, Up 107.7% YoY
Bafna Pharmaceuticals Ltd reported revenue from operations of ₹42.2 Cr (+7.9% YoY) and net profit of ₹2.7 Cr (+107.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹2.7 Cr · +107.7% YoY